Clinical Trials | December 28, 2023
Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China
Innovent will supply sintilimab for the collaborated clinical trial
Innovent will supply sintilimab for the collaborated clinical trial
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
